Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)

The requested reference [15f2a2ca40d6f2fd3b484ab7ee1e4d28b316d162] no longer exists in our database. It has been replaced by the current reference: [f2629013bfbec5104b02f52a4ed7b3b42fbca2ab]

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2015
This article has no abstract
Epistemonikos ID: a07b4e984b1696b8519ccbf0d5b9e794ee46adb0
First added on: Feb 07, 2025